Clinical trials: BCC - Basal Cell Carcinoma
Non-melanomatous Skin Cancer
Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of celecoxib may be an effective way to prevent the development of basal cell carcinoma.
- Trial name
- NCT00023621
- Testing
- celecoxib
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Francisco
Basal Cell Carcinoma, Superficial Basal Cell Carcinoma
Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma
Optical coherence tomography guided laser treatment of basal cell carcinoma
- Conditions
- Basal Cell Carcinoma, Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
- Trial name
- NCT04744935
- Testing
- 1064 nm long-pulse Nd:YAG laser
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Christopher Zachary
Carcinoma, Basal Cell (BCC)
Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China
This is a Phase IV, single arm, multicenter study designed to evaluate the efficacy and safety profile of Sonidegib in chinese participants with locally advanced basal cell carcinoma (laBCC) who are not amenable to radiation…
- Trial name
- NCT06880848
- Testing
- Sonidegib Phosphate Capsules
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Jemincare
Basal Cell Carcinoma
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
The purpose of this study is to investigate the safety and effectiveness of oral vismodegib therapy in the treatment of different 'histologic subtypes' of basal cell skin cancer (BCC).
- Trial name
- NCT01700049
- Testing
- vismodegib (150 mg PO daily)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Superficial Basal Cell Carcinoma
Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults
This is a Phase 2, Single-Arm, Open-Label, Single Center, Proof of Concept Study to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) on the neck, trunk, or…
- Trial name
- NCT05713760
- Testing
- Tirbanibulin Ointment 1%
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Austin Institute for Clinical Research
Non-melanoma Skin Cancer
Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma
Vitamin D has a crucial role in cancer control and prevention.vitamin D receptor (VDR) and its heterodimer Retinoid X receptor (RXR) are equally important in the cell.
- Trial name
- NCT05550766
- Volunteers
- 50 people
- Sponsor
- Sohag University
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
This phase I trial studies the side effects and best dose of photodynamic therapy using HPPH in treating patients who are undergoing surgery for primary or recurrent head and neck cancer.
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Trial name
- NCT00470496
- Testing
- HPPH, photodynamic therapy, conventional surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT05896839
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC).
- Trial name
- NCT03889912
- Testing
- Cemiplimab
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 97 people
- Sponsor
- Regeneron Pharmaceuticals
Skin Basal Cell Carcinoma
Effectiveness of Narrow Margins in Patients With Low-Risk Basal Cell Carcinoma Undergoing Surgery
This clinical trial studies the effectiveness of narrow margins in patients with low-risk basal cell carcinoma undergoing surgery to remove skin lesions on the face.
- Trial name
- NCT02579551
- Testing
- Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Carcinoma, Basal Cell
Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma
This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.
- Trial name
- Imiquimod (NCT00803907)
- Testing
- Imiquimod 5% cream
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Sao Paulo
Non-melanomatous Skin Cancer
Celecoxib in Preventing Skin Cancer
RATIONALE: Celecoxib may be effective in preventing skin cancer by decreasing redness caused by exposure to ultraviolet light and changing potential skin cancer biomarkers.
- Trial name
- NCT00025051
- Testing
- celecoxib, anti-cytokine therapy, antiangiogenesis therapy
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Basal Cell Carcinoma of the Head and Neck
Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N
The purpose of this study is to evaluate anti-PD-1 Neoadjuvant therapy in Basal cell carcinoma to provide a better outcome when administered prior to surgery and provide a therapeutic strategy to avoid surgery altogether.
- Trial name
- NCT04323202
- Testing
- Pembrolizumab, Tissue collection
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Head and Neck Cancer
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects of stereotactic radiosurgery in treating…
- Trial name
- NCT00851253
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
Advanced Solid Tumor Cancers, Medulloblastoma
An East Asian Study of LDE225
The purpose of this study is to determine Maximum Tolerated Dose (MTD) or recommended phase II dose of LDE225 when administered orally to two adult patient groups of East Asian (i.e., Japanese and Chinese/Taiwanese) with advanced…
- Conditions
- Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
- Trial name
- NCT01208831
- Testing
- LDE225
- Where
- 4 sites in Hong Kong, Japan and 1 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Basal Cell Carcinoma
Rates of Positive Basal Cell Carcinomas (BCCs) in Re-excisions
Basal Cell Carcinoma (BCC) is the most common malignant growth in the world. Treatment is primarily surgical with the goal of excising the growth in its entirety.
- Trial name
- NCT01403480
- Volunteers
- 600 people
- Sponsor
- Rambam Health Care Campus
Melanoma, Squamous Cell Carcinoma of the Head and Neck
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
The purpose of this study is to test the safety of a course of injections containing Poly-ICLC in patients with advanced solid tumors that can be easily and safely reached with a needle.
- Conditions
- Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin
- Trial name
- Hiltonol (NCT01984892)
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Nina Bhardwaj
Advanced Solid Tumors, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
- Conditions
- Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC
- Trial name
- NCT04272034
- Testing
- INCB099318
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Incyte Corporation
Skin Tumors, Melanoma
Skin Cancer Screening Education Study
The overall aim of this population-based screening study is to assess whether the skin cancer screening training of family physicians and dermatologists leads to improved screening outcomes.
- Conditions
- Skin Tumors, Melanoma, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- SCSES (NCT02352428)
- Testing
- Skin Cancer Screening Training
- Where
- Canada
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Association of Dermatological Prevention, Germany
Skin Neoplasm, Squamous Cell Carcinoma
Utility of the Skin Cancer Quality of Life Impact Tool
Background: Patient-reported outcome measures (PROMs) provide validated evidence of health and quality of life (QoL) from the patient perspective.
- Conditions
- Skin Neoplasm, Squamous Cell Carcinoma, Basal Cell Carcinoma
- Trial name
- SCQOLIT (NCT02580916)
- Testing
- SCQOLIT questionnaire
- Where
- United Kingdom
- Volunteers
- 318 people
- Sponsor
- Oxford University Hospitals NHS Trust